Renal Cell Carcinoma

Research highlights promising advancements in renal cell carcinoma treatments, focusing on HIF-2α inhibitors and combination therapies for improved patient outcomes.

During a live event, Che-Kai Tsao, MD, MS, and participants considered the tolerability and efficacy benefits of high starting doses vs dose escalation with TKIs in renal cell carcinoma.

Belzutifan shows promising disease control and manageable safety in advanced VHL disease, with notable tumor responses and anemia as a common adverse effect.

A study reveals that lower KIM-1 levels predict better outcomes in advanced renal cell carcinoma patients treated with nivolumab and ipilimumab.

New research identifies CD8+ PD-1+ TIM-3– LAG-3– TILs as promising biomarkers for improved outcomes in metastatic clear cell renal cell carcinoma treatments.

During a live event, Randy F. Sweis, MD, and participants discussed treating non–clear cell renal cell carcinoma based on current data and particular challenges facing patients.

XmAb819 shows promising antitumor activity and safety in advanced clear cell renal cell carcinoma, paving the way for future clinical advancements.

During a live event, Che-Kai Tsao, MD, MS, and participants gave their reasoning for their choice of combination therapy for a 65-year-old patient with high-burden metastatic renal cell carcinoma.

A new trial shows that the combination of belzutifan and lenvatinib improves progression-free survival in advanced renal cell carcinoma patients.

During a live event, Randy F. Sweis, MD, and participants discussed their impressions of combination trials in non–clear cell renal cell carcinoma.

Results of a recent study reveal significant racial differences in renal cell carcinoma histology and outcomes, highlighting the need for ancestry-informed kidney care strategies.

Phase 2 trial CALYPSO reveals no improvement in outcomes for advanced renal cell carcinoma with savolitinib addition, prompting reevaluation of treatment strategies.

Triplet therapy of ciforadenant, nivolumab, and ipilimumab shows safety but lacks efficacy in advanced clear cell kidney cancer.

During a live event, Nizar M. Tannir, MD and participants discussed their takeaways from trial data on recurrent RCC treatment and their personal experiences.

A phase 2 study reveals lenvatinib and everolimus significantly improve progression-free survival in metastatic clear cell RCC compared to cabozantinib.

New triplet therapy combining belzutifan, pembrolizumab, and lenvatinib shows promising efficacy for advanced clear cell renal cell carcinoma, outperforming other regimens.

The OPTIC RCC trial reveals promising outcomes for patients with angiogenic tumors treated with cabozantinib and nivolumab, showcasing high response rates and tumor reduction.

Fruquintinib plus sintilimab significantly enhances progression-free survival in advanced renal cell carcinoma, offering a promising second-line treatment option.

A new study reveals casdatifan's promising efficacy in treating late-stage kidney cancer, showing significant progression-free survival and response rates.

During a live event, Nizar M. Tannir, MD and participants discussed how they think ahead to later lines of therapy when choosing frontline regimens for advanced renal cell carcinoma.

Researchers explore the impact of CD163-positive tumor-associated macrophages on the effectiveness of nivolumab in treating metastatic clear cell renal cell carcinoma.

Pembrolizumab and lenvatinib show promising survival rates and durable responses in advanced non-clear cell renal cell carcinoma, transforming treatment standards.

During a live event, Nataliya Mar, MD, discussed a non–clear cell renal cell carcinoma trial of cabozantinib/nivolumab and how it compares to other combinations.

Explore the evolving treatment strategies for metastatic clear cell renal cell carcinoma, highlighting innovative combination therapies and their efficacy.

During a live event, Nataliya Mar, MD, discussed systemic therapies such as lenvatinib/pembrolizumab in advanced renal cell carcinoma based on recent trials.